Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Analysts broadly rate Pfizer “Hold”: Of 21 analysts, 14 recommend holding, four recommend buying, two recommend selling and one issues a strong-buy rating. The average 12-month price target is approximately $28.39.
• Pfizer exceeded quarterly expectations, reporting $0.77 in adjusted earnings per share and $15.03 billion in revenue, while revenue increased 2.6% year over year. The company reaffirmed full-year 2026 earnings guidance of $2.80–$3.00 per share.
• The company’s quarterly dividend is $0.43 per share, equivalent to a 6.2% yield, but its payout ratio of 226.32% raises questions about dividend sustainability. Institutional investors own approximately 68.36% of Pfizer’s shares.

Pfizer Inc. (NYSE:PFE - Get Free Report) has been assigned an average rating of "Hold" from the twenty-one analysts that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $28.3889.

Several brokerages have recently commented on PFE. UBS Group reaffirmed a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Weiss Ratings upgraded Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 31st. Guggenheim dropped their target price on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 8th. Finally, Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research report on Sunday, September 13th.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer raised its 2026 revenue guidance to approximately $62 billion, providing a favorable indication for sales momentum and potentially supporting earnings expectations. Pfizer Raises 2026 Revenue Guidance to $62 Billion
• Positive Sentiment: Health Canada authorized Pfizer-BioNTech’s Omicron XFG COVID-19 vaccine, expanding the product’s regulatory reach and creating another opportunity for vaccine revenue, although the commercial impact may be limited compared with the pandemic peak. Pfizer BioNTech Gets Canada Vaccine Authorization
• Neutral Sentiment: Novartis India agreed to acquire Pfizer’s Minipress brands for $150 million. The transaction should provide cash and streamline Pfizer’s portfolio, but it also removes established products from the company’s commercial base. Novartis India Acquires Pfizer’s Minipress Brands
• Neutral Sentiment: Investors are focused on management’s messaging regarding dividend priorities, pipeline setbacks and newer oncology partnerships ahead of the Morgan Stanley Global Healthcare Conference. These factors are central to whether Pfizer’s recent rebound can continue. Pfizer What Is Drawing Fresh Attention Now?
• Negative Sentiment: Several reports question whether Pfizer’s roughly 6% dividend yield can keep growing after its long record of annual increases changed. Concerns about payout sustainability and limited growth are likely weighing on income-focused investors. Pfizer’s Dividend Yield Is Enormous
• Negative Sentiment: One market commentary recommends avoiding Pfizer, citing uncertainty around the dividend, pipeline setbacks and the fact that newer products and acquisitions still represent only a relatively small portion of the business. Two High-Yield Dividend Stocks to Buy and One to Avoid

Institutional Investors Weigh In On Pfizer

A number of institutional investors and hedge funds have recently bought and sold shares of PFE. Angeles Wealth Management LLC raised its position in shares of Pfizer by 2.2% during the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company's stock valued at $410,000 after buying an additional 358 shares in the last quarter. Manchester Financial Inc. boosted its holdings in Pfizer by 2.9% during the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company's stock valued at $317,000 after acquiring an additional 365 shares during the period. Vermillion Wealth Management Inc. boosted its stake in shares of Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company's stock valued at $66,000 after purchasing an additional 382 shares during the period. Eagle Capital Management LLC increased its stake in shares of Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company's stock worth $3,554,000 after buying an additional 390 shares during the period. Finally, Delta Financial Advisors LLC increased its position in shares of Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company's stock valued at $709,000 after acquiring an additional 398 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE opened at $27.60 on Friday. The business has a 50-day moving average of $26.70 and a 200-day moving average of $26.38. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer has a 1 year low of $23.58 and a 1 year high of $29.21. The company has a market capitalization of $157.31 billion, a price-to-earnings ratio of 36.32, a price-to-earnings-growth ratio of 1.86 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the firm earned $0.78 earnings per share. Pfizer's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts anticipate that Pfizer will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.